
Kevin E. Weddington
Examiner (ID: 369, Phone: (571)272-0587 , Office: P/1629 )
| Most Active Art Unit | 1629 |
| Art Unit(s) | 1629, 2899, 1614, 1205 |
| Total Applications | 3441 |
| Issued Applications | 2215 |
| Pending Applications | 423 |
| Abandoned Applications | 827 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17937032
[patent_doc_number] => 11471464
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-18
[patent_title] => Pharmaceutical compositions comprising meloxicam
[patent_app_type] => utility
[patent_app_number] => 17/404129
[patent_app_country] => US
[patent_app_date] => 2021-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 33
[patent_no_of_words] => 23814
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17404129
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/404129 | Pharmaceutical compositions comprising meloxicam | Aug 16, 2021 | Issued |
Array
(
[id] => 18018929
[patent_doc_number] => 20220370428
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => USE OF WNT INHIBITOR WNT-C59 IN PREPARATION OF DRUG FOR TREATING SCN5A MUTATION-INDUCED DILATED CARDIOMYOPATHY
[patent_app_type] => utility
[patent_app_number] => 17/637455
[patent_app_country] => US
[patent_app_date] => 2021-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2591
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17637455
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/637455 | Use of Wnt inhibitor Wnt-C59 in preparation of drug for treating SCN5A mutation-induced dilated cardiomyopathy | Aug 5, 2021 | Issued |
Array
(
[id] => 17685763
[patent_doc_number] => 20220193055
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => METHODS OF TREATING NEUROLOGICAL, METABOLIC, AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED PIOGLITAZONE
[patent_app_type] => utility
[patent_app_number] => 17/394589
[patent_app_country] => US
[patent_app_date] => 2021-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20087
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17394589
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/394589 | METHODS OF TREATING NEUROLOGICAL, METABOLIC, AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED PIOGLITAZONE | Aug 4, 2021 | Abandoned |
Array
(
[id] => 17272804
[patent_doc_number] => 20210379002
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => METHODS OF TREATING MIXED DYSLIPIDEMIA
[patent_app_type] => utility
[patent_app_number] => 17/393213
[patent_app_country] => US
[patent_app_date] => 2021-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23833
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 112
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393213
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/393213 | METHODS OF TREATING MIXED DYSLIPIDEMIA | Aug 2, 2021 | Abandoned |
Array
(
[id] => 17241924
[patent_doc_number] => 20210361667
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
[patent_app_type] => utility
[patent_app_number] => 17/392456
[patent_app_country] => US
[patent_app_date] => 2021-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23789
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17392456
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/392456 | Pharmaceutical compositions comprising meloxicam | Aug 2, 2021 | Issued |
Array
(
[id] => 18610763
[patent_doc_number] => 20230277493
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => Digestive Lipase Activity Inhibitor, Blood Triglyceride Concentration Increase Inhibitor, and Fat Absorption Inhibitor
[patent_app_type] => utility
[patent_app_number] => 18/018951
[patent_app_country] => US
[patent_app_date] => 2021-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4707
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18018951
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/018951 | Digestive lipase activity inhibitor, blood triglyceride concentration increase inhibitor, and fat absorption inhibitor | Aug 1, 2021 | Issued |
Array
(
[id] => 18978773
[patent_doc_number] => 11903927
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-20
[patent_title] => Combination treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 17/388208
[patent_app_country] => US
[patent_app_date] => 2021-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 17
[patent_no_of_words] => 13995
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 116
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388208
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/388208 | Combination treatment of cancer | Jul 28, 2021 | Issued |
Array
(
[id] => 17227080
[patent_doc_number] => 20210353636
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
[patent_app_type] => utility
[patent_app_number] => 17/388805
[patent_app_country] => US
[patent_app_date] => 2021-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23807
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388805
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/388805 | Pharmaceutical compositions comprising meloxicam | Jul 28, 2021 | Issued |
Array
(
[id] => 17670839
[patent_doc_number] => 20220184006
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => COMBINATION THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/385008
[patent_app_country] => US
[patent_app_date] => 2021-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55667
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17385008
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/385008 | Combination therapy | Jul 25, 2021 | Issued |
Array
(
[id] => 17198523
[patent_doc_number] => 20210338617
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases
[patent_app_type] => utility
[patent_app_number] => 17/378744
[patent_app_country] => US
[patent_app_date] => 2021-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37230
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378744
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/378744 | Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases | Jul 17, 2021 | Abandoned |
Array
(
[id] => 18737929
[patent_doc_number] => 20230346831
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => METHODS FOR TREATING METASTATIC CANCER USING LOW DOSE CARBON MONOXIDE
[patent_app_type] => utility
[patent_app_number] => 18/016131
[patent_app_country] => US
[patent_app_date] => 2021-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23079
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016131
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/016131 | METHODS FOR TREATING METASTATIC CANCER USING LOW DOSE CARBON MONOXIDE | Jul 14, 2021 | Pending |
Array
(
[id] => 17342128
[patent_doc_number] => 20220008459
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-13
[patent_title] => OPHTHALMIC FORMULATION AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/371303
[patent_app_country] => US
[patent_app_date] => 2021-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8689
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17371303
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/371303 | Ophthalmic formulation and methods of use | Jul 8, 2021 | Issued |
Array
(
[id] => 17312771
[patent_doc_number] => 20210401819
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR
[patent_app_type] => utility
[patent_app_number] => 17/369531
[patent_app_country] => US
[patent_app_date] => 2021-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5126
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17369531
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/369531 | Pharmaceutical composition and preparation method therefor | Jul 6, 2021 | Issued |
Array
(
[id] => 17334678
[patent_doc_number] => 20220001009
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => NOVEL COMPOSITIONS INCLUDING A THERAPEUTIC ANTIBODIES AND/OR A CHECKPOINT INHIBITOR AND AN INTEGRIN ACTIVATING COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/362512
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14986
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17362512
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/362512 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | Jun 28, 2021 | Issued |
Array
(
[id] => 19372884
[patent_doc_number] => 12064423
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-20
[patent_title] => Medicine combinations and treatment of restless leg syndrome
[patent_app_type] => utility
[patent_app_number] => 17/304414
[patent_app_country] => US
[patent_app_date] => 2021-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8255
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17304414
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/304414 | Medicine combinations and treatment of restless leg syndrome | Jun 20, 2021 | Issued |
Array
(
[id] => 17290885
[patent_doc_number] => 20210386724
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => METHODS OF USING A PHARMACEUTICAL COMPOSITION CONTAINING PIRFENIDONE IN SUSTAINED-RELEASE TABLET FORM
[patent_app_type] => utility
[patent_app_number] => 17/351151
[patent_app_country] => US
[patent_app_date] => 2021-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7841
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351151
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/351151 | Methods of using a pharmaceutical composition containing pirfenidone in sustained-release tablet form | Jun 16, 2021 | Issued |
Array
(
[id] => 19578810
[patent_doc_number] => 12144892
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-19
[patent_title] => Pharmaceutical composition
[patent_app_type] => utility
[patent_app_number] => 17/347989
[patent_app_country] => US
[patent_app_date] => 2021-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 11
[patent_no_of_words] => 6809
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17347989
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/347989 | Pharmaceutical composition | Jun 14, 2021 | Issued |
Array
(
[id] => 19578810
[patent_doc_number] => 12144892
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-19
[patent_title] => Pharmaceutical composition
[patent_app_type] => utility
[patent_app_number] => 17/347989
[patent_app_country] => US
[patent_app_date] => 2021-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 11
[patent_no_of_words] => 6809
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17347989
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/347989 | Pharmaceutical composition | Jun 14, 2021 | Issued |
Array
(
[id] => 19578810
[patent_doc_number] => 12144892
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-19
[patent_title] => Pharmaceutical composition
[patent_app_type] => utility
[patent_app_number] => 17/347989
[patent_app_country] => US
[patent_app_date] => 2021-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 11
[patent_no_of_words] => 6809
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17347989
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/347989 | Pharmaceutical composition | Jun 14, 2021 | Issued |
Array
(
[id] => 19578810
[patent_doc_number] => 12144892
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-19
[patent_title] => Pharmaceutical composition
[patent_app_type] => utility
[patent_app_number] => 17/347989
[patent_app_country] => US
[patent_app_date] => 2021-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 11
[patent_no_of_words] => 6809
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17347989
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/347989 | Pharmaceutical composition | Jun 14, 2021 | Issued |